Mylan Inc looks to expand in India
Launches six products targeted at Indian women, many more are in the offing Hyderabad: Mylan Inc, which acquired the city-based Matrix Laboratories...
Launches six products targeted at Indian women, many more are in the offing
Hyderabad: Mylan Inc, which acquired the city-based Matrix Laboratories Limited in 2006, is now increasing its focus on the country's expanding pharmaceutical market through a slew of new launches.
The US-based pharma major which operates in India through Mylan Pharmaceuticals Private Limited has on Friday launched eight new products which are exclusively targeted at women. This new portfolio of Women's Care products which will initially consist of eight products focuses on therapies such as hormones, pre- and post-natal nutrition and management of premenstrual syndrome (PMS). This launch builds on Mylan's launch of a comprehensive portfolio of antiretroviral products in India last year.
"The launch of Mylan's Women's Care portfolio expands and strengthens our growing commercial platform in India and further delivers on our commitment to provide the world's population with access to high quality medicine. Women's Care represents a high-growth therapeutic category in India and an opportunity for Mylan to help satisfy unmet medical need," said Heather Bresch, CEO, Mylan. More than 85 per cent of childbearing age women in India suffer from PMS, nearly one in five pregnancies in Indian women end in miscarriage, and it is estimated that the number of infertile couples in India is around 12 million, he added.
Mylan feels that addressing the risks of miscarriages, infertility and nutritional deficiencies continues to be the key challenge in women's health. "In addition to launching our innovative, high quality product portfolio, Mylan will help to strengthen the capabilities of health care providers in this area through training programs and workshops, working together with the medical community to address areas of concern in women's health and improve timely access to appropriate high quality treatment," Bresch explained.
Mylan president Rajiv Malik strongly felt that the addition of Women's Care portfolio would further consolidate the company's position in the growing Indian market. "We will continue to expand into new therapeutic categories, besides increasing our field force and leveraging our strong distribution capabilities in India to support future product launches," Malik said.
Mylan, which markets its products across 140 countries, has 1,100 generic pharmaceuticals and branded products in its portfolio. Besides, it offers a wide range of antiretroviral therapies on which nearly 40 per cent of HIV/AIDS patients in developing countries depend. The Pennsylvania-based generics major employs close to 20,000 people globally.